Biomarkers and surrogate outcome measures can be used to monitor disease development, but what can biomarkers tell us about disease processes in axial spondyloarthritis? New research suggests that some biomarkers might be useful in monitoring patients with ankylosing spondylitis, but greater understanding of the pathological mechanisms is needed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Braun, J. & Baraliakos, X. Imaging of axial spondyloarthritis including ankylosing spondylitis. Ann. Rheum. Dis. 70 (Suppl. 1), i97–i103 (2011).
Lassere, M. et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J. Rheumatol. 34, 607–615 (2007).
Pedersen, S. J. et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann. Rheum. Dis. 70, 1375–1381 (2011).
Pedersen, S. J. et al. Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondyloarthritis treated with TNFα inhibitors. A study of radiographic progression, MRI inflammation and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover. Arthritis Rheum. http://dx.doi.org/10.1002/art.30627.
Visvanathan, S. et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann. Rheum. Dis. 67, 511–517 (2008).
Maksymowych, W. P. et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum. 56, 1846–1853 (2007).
Visvanathan, S. et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann. Rheum. Dis. 68, 175–182 (2009).
Baraliakos, X., Listing, J., Rudwaleit, M., Sieper, J. & Braun, J. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res. Ther. 10, R104 (2008).
Chiowchanwisawakit, P., Lambert, R. G., Conner-Spady, B. & Maksymowych, W. P. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum. 63, 2215–2225 (2011).
Appel, H. et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 60, 3257–3262 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Braun, J., Baraliakos, X. The disease process in axial SpA: what can biomarkers tell us?. Nat Rev Rheumatol 8, 8–10 (2012). https://doi.org/10.1038/nrrheum.2011.187
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2011.187
